Botanix Pharmaceuticals : Roadshow Presentation

For personal use only

8 December 2021

Botanix Roadshow Presentation

Key highlights

• Botanix has released a corporate presentation being utilized for a non-deal roadshow with institutional investors this week, as well as a presentation at the Switzer Small and Micro Cap Virtual Investor Day taking place today
• Presentation updates on the progress of the BTX 1702 rosacea clinical study, with recruitment progressing well towards completion in mid 2022, as well as progress towards commencing the BTX 1801 Phase 2b antimicrobial study in early 2022 and completion of the BTX 1204A pilot study in canines with atopic dermatitis in 1H 2022
• Botanix remains in a strong financial position, holding cash balance of A$19.57m at 30 September 2021

Philadelphia PA and Perth Australia, 8 December 2021: Clinical dermatology company, Botanix

Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to release an updated corporate presentation as attached.

The presentation is being utilised as part of meetings with investors being conducted this week as well as a presentation at the Switzer Small and Micro Cap Virtual Investor Day. Botanix is in a strong financial position and so no capital raising is planned arising from these meetings.

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage dermatology company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two complimentary development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities.

The Company is developing a pipeline of product candidates with recent positive data from its BTX 1801 Phase 2a antimicrobial study and its Phase 1b/2a rosacea clinical study is currently enrolling patients. Following a successful meeting with the FDA, the Company has also confirmed a drug

For personal use only

development plan for the BTX 1503 acne Phase 3 program to support registration. In addition, Botanix is advancing its BTX 1204A atop dermatitis program to a proof of concept canine study, following encouraging early data from a recent pilot study. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: [phone]	P: [phone]	P: [phone]
[e-mail]	[e-mail]	[e-mail]

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

ersonal use only

Investor Presentation

December 2021

World class team

Botanix: World Class Board and Management team

onlyBoard of Directors

Vince Ippolito

President and Executive Chairman

Matt Callahan	Dr Bill Bosch
Executive Director	Executive Director

Dr Stewart Washer

Director

use

• COO of Anacor and Medicis with 17 years at Novartis
• More than 30 years experience in pharma with 20+ years within dermatology

• Serial founder and ex-investment director of two venture capital firms in life sciences
• Developed four products through FDA approval and launch

• 20+ years experience in pharma industry
• Co-inventorof SoluMatrix™ drug delivery technology and NanoCrystal® Technology

• Currently a board member of Orthocell, Cynata Therapeutics and Emyria
• 20+ years of experience in medical tech, biotech and agrifood

Executive Management

Dr Clarence Young	Anthony Robinson	Lynda Berne	Dr Jack Hoblitzell
Chief Medical Officer	VP of Development	Head of Commercial	SVP Pharmaceutical Development

Dr Ira Lawrence

Advisor

ersonal

& Advisers

 Recently Chief Medical Officer	 Recently Vice President at	 Founder of BAL Pharma
at Velicept Therapeutics	Advicenne	Consulting
 Senior leadership roles at	 Senior leadership roles at	 13 years senior leadership
Iroko Pharmaceuticals,	Aquestive Therapeutics,	roles in pharmaceuticals
Novartis and GlaxoSmithKline	Intrommune and Shire	industry
	Pharmaceuticals

• 30+ years leading world-class technical operations to manufacture and deliver pharmaceuticals
• Senior leadership roles at Assertio Therapeutics , Pfizer, King, Ivax and Teva

• 30+ years of senior level leadership experience within the global pharmaceutical and medical device industries

2

www.botanixpharma.com

Botanix Pharmaceuticals: a leader in topical drug development

Clinical stage dermatology company developing new treatments for common skin diseases and infection, leveraging its novel delivery technology Permetrex ™

only		Pharmaceutical focus	Leveraging novel skin delivery technology (Permetrex™) and novel drug mechanisms
			of action, including synthetic cannabidiol (CBD)
use		Topically driven	Targeting key dermatology and antimicrobial indications with topical treatments that
		are safe, well tolerated and validated by clinical efficacy
	Significant markets	Pipeline targeting multi-billion dollar markets with no new products approved by FDA in
			decades for these indications, with physician and patient demand for new treatments
ersonal		World-class team	World-class and experienced team with significant dermatology and antimicrobial
			drug track record and development expertise
		Near-term catalysts	Multiple upcoming catalysts including completion of Phase 1b/2 rosacea study,
		commencement Phase 2 antimicrobial study, canine AD data readout and new
			Permetrex™ opportunities
			3
			www.botanixpharma.com